Main Navigation

• The Children's Inn
• National Cancer Institute, Childhood Cancers
• NIH Clinical Center
• Camp Fantastic

Pediatric Oncology Branch Home > Clinical Programs > Pharmacology and Experimental Therapeutics (Phase I/II) and Genetic Tumor Predisposition

Headline Title

Pharmacology and Experimental Therapeutics (Phase I/II)

The goal of the Pharmacology & Experimental Therapeutics (PET) Section is to develop more effective treatments for children and young adults with cancers. Our early clinical trials target children with refractory cancers, for whom no curative treatment exists. Drugs with new and different mechanisms of action are developed in trials called phase I or phase II trials. In addition to an active early clinical trials program for children with refractory cancers, the PET Section has established a program for children and young adults who are predisposed to the development of tumors due to a genetic disorder such as neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and medullary thyroid carcinoma.

In this section:
Staff
Clinical Trials
Contact Information

return to the top